2.2B
Total Engagement (90d)
Basket social engagement over time
Total daily engagement across the GLP-1 + CGM basket. Watch where social leads price.
The leaderboard
Ranked by 90-day engagement. Click a header to sort. Sentiment 0-100 with 30-day change; momentum is week-over-week interactions.
| Rank ▼ |
Name |
Class |
Engagement (90d) |
Sentiment |
Momentum w/w |
Galaxy |
Price |
| 1 |
Ozempic
$NVO |
GLP-1 |
1.0B |
14 -43 |
-54% |
0 |
— |
| 2 |
Mounjaro
$LLY |
GLP-1 |
339.0M |
51 -3 |
-14% |
0 |
— |
| 3 |
Novo Nordisk
$NVO |
Stock |
276.1M |
96 -2 |
+32% |
56 |
— |
| 4 |
Eli Lilly
$LLY |
Stock |
200.4M |
23 -59 |
-15% |
63 |
$1,162.31 |
| 5 |
Wegovy
$NVO |
GLP-1 |
154.6M |
52 -2 |
-62% |
0 |
— |
| 6 |
Omnipod
$PODD |
Pump |
113.0M |
40 -45 |
-16% |
0 |
— |
| 7 |
Zepbound
$LLY |
GLP-1 |
60.1M |
53 -4 |
-31% |
0 |
— |
| 8 |
FreeStyle Libre
$ABT |
CGM |
14.4M |
64 -7 |
+171% |
0 |
— |
| 9 |
Intuitive Surgical
$ISRG |
Robotics |
6.7M |
92 +7 |
+120% |
63 |
$421.72 |
| 10 |
DexCom
$DXCM |
CGM |
688.4K |
71 -22 |
+128% |
65 |
$77.14 |
Desk note
GLP-1 drugs dominate the diabetes-care conversation: Ozempic ($NVO) leads with 1.0B engagements over the window. The hottest mover this week is FreeStyle Libre (interactions +171% w/w). Watch the CGM names (DexCom, FreeStyle Libre, Omnipod) for share-of-voice shifts and complaint clusters, and the GLP-1 names for supply and adverse-event chatter, both of which lead the print. Peak basket engagement landed on Apr 07.
Built from live LunarCrush data. Social/market-intelligence signal to inform research, not investment advice. When deployed, this refreshes on a schedule. Powered by LunarCrush.